Drug Profile

LT 5001

Alternative Names: LT-5001

Latest Information Update: 22 May 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Lumosa Therapeutics
Class Antipruritics
Mechanism of Action Opioid kappa receptor agonists; Opioid mu receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Pruritus

Highest Development Phases

Phase I/II Pruritus

Most Recent Events

15 May 2020 Phase-I/II clinical trials in Pruritus (In adults, In the elderly) in Taiwan (Topical) (NCT04393675)
03 Dec 2019 Lumosa Therapeutics plans a proof of concept phase Ib/II trial for Pruritus in Taiwan (Topical, Ointment) in fourth quarter of 2019 (Lumosa Therapeutics website, December 2019)
03 Dec 2019 LT 5001 is available for licensing as of 03 Dec 2019 (Lumosa Therapeutics website, December 2019)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com